-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F6lNjKqk4NIdkZk55zxkHn94ZEoZMhRauWX3foUYOfpQSkYScw/vfh9McgbjlD66 KlELnYjpCEyIKlbBF+D08w== 0001193125-09-249307.txt : 20091208 0001193125-09-249307.hdr.sgml : 20091208 20091208163041 ACCESSION NUMBER: 0001193125-09-249307 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20091202 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20091208 DATE AS OF CHANGE: 20091208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARGACEPT INC CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 091228984 BUSINESS ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 BUSINESS PHONE: 3364802100 MAIL ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2009

 

 

TARGACEPT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51173   56-2020050

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

200 East First Street, Suite 300

Winston-Salem, North Carolina

   27101
(Address of principal executive offices)   (Zip Code)

(336) 480–2100

Registrant’s telephone number, including area code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On December 2, 2009, the Board of Directors (the “Board”) of Targacept, Inc. (the “Company”), acting upon the recommendation of the Board’s Compensation Committee, awarded a special bonus to J. Donald deBethizy, President and Chief Executive Officer, and authorized Dr. deBethizy to award within specified parameters a special bonus to each of the Company’s other executive officers, including its named executive officers. The special bonuses were awarded in recognition of the contributions by the Company’s executive officers to the overall performance and achievement of the Company during 2009 and are in addition to amounts to be awarded for 2009 under the Company’s annual incentive award program. The respective amounts awarded to the Company’s executive officers are set forth below.

 

J. Donald deBethizy      President and Chief Executive Officer    $ 100,000
Peter A. Zorn      Vice President, Legal Affairs, General Counsel and Secretary    $ 75,000
Jeffrey P. Brennan      Vice President, Business and Commercial Development    $ 65,000
Geoffrey C. Dunbar      Vice President, Clinical Development and Regulatory Affairs    $ 60,000
Alan A. Musso      Vice President, Chief Financial Officer and Treasurer    $ 60,000
Merouane Bencherif      Vice President, Preclinical Research    $ 50,000
William C. Caldwell      Vice President, Drug Discovery and Development    $ 50,000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        TARGACEPT, INC.
Date: December 8, 2009       /S/    ALAN A. MUSSO      
       

Alan A. Musso

Vice President, Chief Financial Officer and

Treasurer

 -----END PRIVACY-ENHANCED MESSAGE-----